United States · Bill · HR
H.R. 6973 (117th)
Enhanced Access to Affordable Medicines Act of 2022
Introduced
8 March 2022
Last action
—
Status
Referred to the Subcommittee on Health.
Sponsors
—
Subjects
Discovery layer
Source updated
7 April 2025
Summary
Enhanced Access to Affordable Medicines Act of 2022 This bill specifies that the Food and Drug Administration may approve generic drugs with different labels than the brand-name versions if, among other requirements, the brand-name drug is subject to an active patent or exclusivity period and a revised label for the brand-name drug is approved within 90 days (rather than 60 days) of the expiration of the patent or exclusivity period.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
3 official files
Introduced in House (text)
Introduced in House (text)
Introduced in House · EN · 8 March 2022
Introduced in House (PDF)
Introduced in House · EN · 8 March 2022
Introduced in House
summary · EN · 8 March 2022
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/117th-congress/house-bill/6973
- Open data entity: https://api.congress.gov/v3/bill/117/hr/6973